| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $202.9M | +79.9% |
| SG&A Expense | $42.0M | +38.4% |
| Operating Income | -$244.8M | -71.1% |
| Pre-tax Income | -$229.7M | -89.9% |
| Income Tax | $611K | +116.5% |
| Net Income | -$227.3M | -91.1% |
| EPS (Basic) | -$3.53 | -86.8% |
| EPS (Diluted) | -$3.53 | -86.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $334.5M | +85.4% |
| Current Assets | $421.7M | -11.1% |
| Total Assets | $424.4M | -11.2% |
| Current Liabilities | $45.5M | +102.4% |
| Long-term Debt | $74.1M | — |
| Total Liabilities | $120.0M | +388.8% |
| Stockholders' Equity | $304.5M | -31.9% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$196.0M | -68.1% |
| Capital Expenditures | $35K | -93.3% |
| Investing Cash Flow | $203.0M | +198.7% |
| Financing Cash Flow | $146.0M | +184.5% |
| Free Cash Flow | -$196.0M | -67.4% |